Țară: Regatul Unit
Limbă: engleză
Sursă: MHRA (Medicines & Healthcare Products Regulatory Agency)
Irinotecan hydrochloride trihydrate
Accord-UK Ltd
L01CE02
Irinotecan hydrochloride trihydrate
20mg/1ml
Solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 08010500; GTIN: 5055565729786
PACKAGE LEAFLET: INFORMATION FOR THE USER IRINOTECAN HYDROCHLORIDE 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION irinotecan hydrochloride trihydrate The name of your medicine is ‘Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion’ but in the rest of the leaflet it will be called “Irinotecan Injection”. Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. IN THIS LEAFLET: 1. What Irinotecan Injection is and what it is used for 2. What you need to know before you are given Irinotecan Injection 3. How you will be given Irinotecan Injection 4. Possible side effects 5. How to store Irinotecan Injection 6. Contents of the pack and other information 1. WHAT IRINOTECAN INJECTION IS AND WHAT IT IS USED FOR Irinotecan belongs to a group of medicines called cytostatics (anti-cancer medicines). Irinotecan is used for the treatment of advanced cancer of the colon and rectum in adults, either in a combination with other medicines or alone. Your doctor may use a combination of Irinotecan with 5-FLUOROURACIL/FOLINIC ACID (5FU/FA) and BEVACIZUMAB to treat your CANCER OF THE LARGE INTESTINE (COLON OR RECTUM). Your doctor may use a combination of Irinotecan with CAPECITABINE with or without BEVACIZUMAB to treat your CANCER OF THE COLON AND RECTUM. Your doctor may use a combination of Irinotecan with CETUXIMAB to treat a particular type of CANCER OF THE LARGE INTESTINE (KRAS WILD-TYPE) which expresses a protein called EGFR. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN IRINOTECAN INJECTION YOU SHOULD NOT BE GIVEN IRINOTECAN INJECTION IF YOU are allergic to Irinotecan Injection or any of the other ingredie Citiți documentul complet
OBJECT 1 IRINOTECAN HYDROCHLORIDE ACCORD 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 07-Apr-2018 | Accord Healthcare Limited 1. Name of the medicinal product Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion 2. Qualitative and quantitative composition One ml of concentrate contains 20 mg irinotecan hydrochloride trihydrate equivalent to 17.33 mg irinotecan. Each vial of 2 ml contains 40 mg of irinotecan hydrochloride trihydrate (40 mg/2 ml) Each vial of 5 ml contains 100 mg of irinotecan hydrochloride trihydrate (100 mg/5 ml) Each vial of 15 ml contains 300 mg of irinotecan hydrochloride trihydrate (300 mg/15 ml) Each vial of 25 ml contains 500 mg of irinotecan hydrochloride trihydrate (500 mg/25 ml) Excipient with known effect Each ml contains 45 mg sorbitol. For a full list of excipients, see section 6.1. 3. Pharmaceutical form Concentrate for solution for infusion. A pale yellow clear solution practically free from particles. pH in the range of approximately 3.0 to 3.8 and osmolality in the range of approximately 270 to 330 mOsmol/kg. 4. Clinical particulars 4.1 Therapeutic indications Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion is indicated for the treatment of patients with advanced colorectal cancer: • In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, • As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild- type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy. (see section 5.1) Irinotecan Hydrochloride 20 mg/ml Concentrate for Solution for Infusion in combination with 5- fluorouracil, foli Citiți documentul complet